Claus Kremoser

2.5k total citations · 1 hit paper
32 papers, 2.0k citations indexed

About

Claus Kremoser is a scholar working on Oncology, Epidemiology and Surgery. According to data from OpenAlex, Claus Kremoser has authored 32 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Epidemiology and 9 papers in Surgery. Recurrent topics in Claus Kremoser's work include Drug Transport and Resistance Mechanisms (16 papers), Liver Disease Diagnosis and Treatment (11 papers) and Cholesterol and Lipid Metabolism (7 papers). Claus Kremoser is often cited by papers focused on Drug Transport and Resistance Mechanisms (16 papers), Liver Disease Diagnosis and Treatment (11 papers) and Cholesterol and Lipid Metabolism (7 papers). Claus Kremoser collaborates with scholars based in United States, Germany and Austria. Claus Kremoser's co-authors include Friedrich Bonhoeffer, Uwe Drescher, Masaharu Noda, Claudia Handwerker, Ulrich Deuschle, Olaf Kinzel, Eva Hambruch, Andreas Schulz, Christian Gege and Michael Burnet and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Claus Kremoser

31 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In vitro guidance of retinal ganglion cell axons by RAGS, a 25 kDa tectal protein related to ligands for Eph receptor tyrosine kinases

1995 702 citations Uwe Drescher, Claus Kremoser et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claus Kremoser United States	17	815	724	585	504	430	32	2.0k
G. Hege Thoresen Norway	26	1.2k 1.4×	141 0.2×	203 0.3×	218 0.4×	337 0.8×	93	2.0k
Haowei Song United States	26	1.1k 1.4×	165 0.2×	115 0.2×	325 0.6×	327 0.8×	38	2.3k
Riccardo Autelli Italy	20	718 0.9×	116 0.2×	131 0.2×	339 0.7×	125 0.3×	37	1.6k
Chantal Filloux France	21	1.3k 1.6×	187 0.3×	474 0.8×	393 0.8×	339 0.8×	25	2.2k
Guy E. Groblewski United States	25	1.0k 1.2×	194 0.3×	259 0.4×	179 0.4×	537 1.2×	60	1.9k
Catherine Legraverend France	24	904 1.1×	215 0.3×	297 0.5×	65 0.1×	143 0.3×	36	2.0k
Lei Yin United States	27	913 1.1×	98 0.1×	123 0.2×	505 1.0×	244 0.6×	44	2.1k
Gregory Murphy United Kingdom	14	1.6k 1.9×	231 0.3×	191 0.3×	113 0.2×	255 0.6×	20	2.1k
Fuminori Tsuruta Japan	15	1.4k 1.7×	303 0.4×	168 0.3×	141 0.3×	75 0.2×	37	1.8k
Gisela Beutner United States	22	2.6k 3.1×	438 0.6×	89 0.2×	243 0.5×	98 0.2×	34	3.0k

Countries citing papers authored by Claus Kremoser

Since Specialization

Citations

This map shows the geographic impact of Claus Kremoser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claus Kremoser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claus Kremoser more than expected).

Fields of papers citing papers by Claus Kremoser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claus Kremoser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claus Kremoser. The network helps show where Claus Kremoser may publish in the future.

Co-authorship network of co-authors of Claus Kremoser

This figure shows the co-authorship network connecting the top 25 collaborators of Claus Kremoser. A scholar is included among the top collaborators of Claus Kremoser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claus Kremoser. Claus Kremoser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Benegiamo, Giorgia, Archana Vijayakumar, Masaki Kimura, et al.. (2026). An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial. Nature Medicine. 32(3). 883–893.

Hollenback, David, Eva Hambruch, Andreas Schulz, et al.. (2024). Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease. Journal of Pharmacology and Experimental Therapeutics. 389(1). 61–75. 3 indexed citations

Schwabl, Philipp, Eva Hambruch, Grant R. Budas, et al.. (2021). The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines. 9(1). 60–60. 49 indexed citations

Gege, Christian, Eva Hambruch, Nina Hambruch, Olaf Kinzel, & Claus Kremoser. (2019). Nonsteroidal FXR Ligands: Current Status and Clinical Applications. Handbook of experimental pharmacology. 256. 167–205. 67 indexed citations

Hambruch, Nina, Barbara Herkert, Christian Gege, et al.. (2019). Abstract 3588: Identification of a potent, orally bioavailable and selective MCT4 Inhibitor for the treatment of solid Warburg tumors. 3588–3588. 1 indexed citations

Hambruch, Eva, David Hollenback, Olaf Kinzel, et al.. (2019). FRI-303-How to develop a differentiated FXR agonist: GS-9674 shows a reduced side effect profile in mice, monkeys amd human phase 1 studies compared to its predecessor Px-102. Journal of Hepatology. 70(1). e528–e529. 2 indexed citations

Worthmann, Anna, Clara John, Malte Rühlemann, et al.. (2017). Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. Nature Medicine. 23(7). 839–849. 227 indexed citations

Schwabl, Philipp, Eva Hambruch, Hubert Hayden, et al.. (2016). The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. Journal of Hepatology. 66(4). 724–733. 137 indexed citations

Kinzel, Olaf, Christoph Steeneck, Thomas Schlüter, et al.. (2016). Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties. Bioorganic & Medicinal Chemistry Letters. 26(15). 3746–3753. 27 indexed citations

10.

Schwabl, Philipp, Eva Hambruch, Michael Burnet, et al.. (2016). The Non-Steroidal Fxr Agonist Gs-9674 Reduces Liver Fibrosis and Ameliorates Portal Hypertension in a Rat Nash Model. Journal of Hepatology. 64(2). S165–S166. 8 indexed citations

11.

Schwabl, Philipp, Eva Hambruch, B.A. Payer, et al.. (2015). G18 : The FXR agonist PX20606 reduces liver damage, fibrosis and portal hypertension in cirrhotic rats. Journal of Hepatology. 62. S238–S238. 2 indexed citations

12.

Gege, Christian, Olaf Kinzel, Christoph Steeneck, Andreas Schulz, & Claus Kremoser. (2014). Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities. Current Topics in Medicinal Chemistry. 14(19). 2143–2158. 52 indexed citations

13.

Podszun, Maren C., et al.. (2014). Dietary α-tocopherol and atorvastatin reduce high-fat-induced lipid accumulation and down-regulate CD36 protein in the liver of guinea pigs. The Journal of Nutritional Biochemistry. 25(5). 573–579. 40 indexed citations

14.

Deuschle, Ulrich, Julia Schüler, Andreas Schulz, et al.. (2012). FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model. PLoS ONE. 7(10). e43044–e43044. 72 indexed citations

15.

Hambruch, Eva, Shinobu Miyazaki‐Anzai, Ulrike K. Hahn, et al.. (2012). Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice. Journal of Pharmacology and Experimental Therapeutics. 343(3). 556–567. 87 indexed citations

16.

Abel, Ulrich, Thomas Schlüter, Andreas Schulz, et al.. (2010). Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorganic & Medicinal Chemistry Letters. 20(16). 4911–4917. 47 indexed citations

17.

Kremoser, Claus, M. Albers, Thomas P. Burris, Ulrich Deuschle, & Manfred Koegl. (2007). Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators. Drug Discovery Today. 12(19-20). 860–869. 19 indexed citations

18.

Albers, M., Beatrix Blume, Matthew B. Wright, et al.. (2005). A Novel Principle for Partial Agonism of Liver X Receptor Ligands. Journal of Biological Chemistry. 281(8). 4920–4930. 78 indexed citations

19.

Ciossek, Thomas, Claus Kremoser, Susanne Lang, et al.. (1998). Eph receptor–ligand interactions are necessary for guidance of retinal ganglion cell axons in vitro. European Journal of Neuroscience. 10(5). 1574–1580. 51 indexed citations

20.

Drescher, Uwe, et al.. (1995). In vitro guidance of retinal ganglion cell axons by RAGS, a 25 kDa tectal protein related to ligands for Eph receptor tyrosine kinases. Cell. 82(3). 359–370. 702 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact